ВОЗМОЖНОСТИ АДЪЮВАНТНОЙ ЭНДОКРИННОЙ ТЕРАПИИ РАКА МОЛОЧНОЙ ЖЕЛЕЗЫ (часть II*)
https://doi.org/10.17650/1994-4098-2008-0-4-37-42
Аннотация
ВОЗМОЖНОСТИ АДЪЮВАНТНОЙ ЭНДОКРИННОЙ ТЕРАПИИ РАКА МОЛОЧНОЙ ЖЕЛЕЗЫ (часть II*)
Об авторах
Н. Ю. ДобровольскаяРоссия
Э. К. Ввозный
Россия
Ю. М. Бычков
Россия
Список литературы
1. Cuzick J., Powles T., Veronesi U. et al. Overview of the main outcomes in breast- cancer prevention trials. Lancet 2003;361:296—300.
2. Braithwaite R.S., Chlebowski R.T., Lau J. et al. Meta-analysis of vascular and neoplastic events associated with tamoxifen. J Gen Intern Med 2003;18:937—47.
3. Lewis S. Do endocrine treatments for breast cancer have a negative impact on lipid profiles and cardiovascular risk in postmenopausal women? Am Heart J 2007;153:182—8.
4. Wysowski D.K., Honig S., Beitz J. Uterine sarcoma associated with tamox- ifen use. N Engl J Med 2002;346:1832—3.
5. ATAC Trialists’ Group. Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years’ adjuvant treatment for breast can- cer. Lancet 2005;365:60—2.
6. Coates A.S., Keshaviah A., Thurlimann B. et al. Five years of letro- zole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BIG 1— 98. J Clin Oncol 2007;25:486—92.
7. Coombes R.C., Kilburn L.S., Snowdon C.F. et al. Survival and safety of exemestane versus tamoxifen after 2—3 years’ tamoxifen treatment (Intergroup Exemestane Study): a randomised con- trolled trial. Lancet 2007;369:559—70.
8. Winer E.P., Hudis C., Burstein H.J. et al. American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for postmenopausal women with hormone receptor-positive breast cancer: status report 2004. J Clin Oncol 2005;23:619—29.
9. The ATAC Trialists’ Group. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial. Lancet 2002;359:2131—9.
10. The ATAC Trialists’ Group. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early-stage breast cancer. Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial efficacy and safety update analyses. Cancer 2003;98:1802—10.
11. Goldhirsch A., Wood W., Gelber R. et al. Progress and promise: highlights of the international expert consensus on the primary therapy of early breast cancer 2007. Ann Oncol 2007;18:1133—44.
12. Viale G., Regan M.M., Maiorano E. et al. Prognostic and predictive value of centrally reviewed expression of estrogen and progesterone receptors in a random- ized trial comparing letrozole and tamox- ifen adjuvant therapy for postmenopausal early breast cancer: BIG 1—98. J Clin Oncol 2007;25:3846—52.
13. Dowsett M., Allred D.C., on behalf of the TransATAC Investigators. Relationship between quantitative ER and PgR expres- sion and Her-2 status with recurrence in the ATAC trial. Breast Cancer Res Treat 2006;100 (suppl 1):21 (abstr 48).
14. Cox D.R. Regression models and life tables. J R Stat Soc 1972;34:187—220.
15. Jones M.C., Wand M.P. Kernel smoothing. Boca Raton, FL: CRC Press; 1994.
16. Food and Drug Administration (COSTART). The coding symbols for thesaurus of adverse reaction terms, 5th ed; 1995.
17. Hanrahan E.O., Gonzalez-Angulo A.M., Giordano S.H. et al. Overall survival and cause-specific mortality of patients with stage T1a,bN0M0 breast carcinoma. J Clin Oncol 2007;25:4952—60.
18. The ATAC Trialists’ Group. Comprehensive side-effect profile of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: long-term safety analysis of the ATAC trial. Lancet Oncol 2006;7:633—43.
19. Coleman R.E., on behalf of the ATAC Trialists’ Group. Effect of anastro- zole on bone mineral density: 5-year results from the Arimidex, Tamoxifen, Alone or in Combination (ATAC) trial. Proc ASCO 2006;24:18. Abstr 511.
20. Eastell R., Adams J.E., Coleman R. et al. Effect of anastrozole on bone min- eral density: 5-year results from the ATAC trial (18233230). J Clin Oncol 2008;26(7):1051—7.
21. Eastell R., Van Poznack C., Hannon R.A. et al. The SABRE (Study of Anastrozole with the Bisphosphonate Risedronat E) study: 12-month analysis. J Bone Miner Res 2007;22(suppl 1):113.
22. Singh S., Cuzick J., Edward R. et al. Effect of anastrozole on bone mineral density after one year of treatment: results from bone sub-study of the International Breast Cancer Prevention Study (IBIS-II). Breast Cancer Res Treat 2007;106(suppl 1):9. Abstr 28.
23. Fisher B., Costantino J.P., Redmond C.K. et al. Endometrial cancer in tamoxifen-treated breast cancer patients: findings from the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-14. J Natl Cancer Inst 1994;86:527—37.
24. Jakesz R., Kaufmann M., Gnant M. et al. Benefits of switching post- menopausal women with hormone-sensi- tive early breast cancer to anastrozole after 2 years adjuvant tamoxifen: com- bined results from 3,123 women enrolled in the ABCSG Trial 8 and the ARNO 95 Trial. San Antonio Breast Cancer Conference; 2004. Abstr. 2.
Рецензия
Для цитирования:
Добровольская Н.Ю., Ввозный Э.К., Бычков Ю.М. ВОЗМОЖНОСТИ АДЪЮВАНТНОЙ ЭНДОКРИННОЙ ТЕРАПИИ РАКА МОЛОЧНОЙ ЖЕЛЕЗЫ (часть II*). Опухоли женской репродуктивной системы. 2008;(4):37-42. https://doi.org/10.17650/1994-4098-2008-0-4-37-42
For citation:
Dobrovolskaya N.Yu., Vvoznyi E.K., Bychkov Yu.M. Potentialities of adjuvant endocrine therapy for breast cancer (Part II). Tumors of female reproductive system. 2008;(4):37-42. (In Russ.) https://doi.org/10.17650/1994-4098-2008-0-4-37-42